1. Home
  2. PCYO vs SERA Comparison

PCYO vs SERA Comparison

Compare PCYO & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pure Cycle Corporation

PCYO

Pure Cycle Corporation

HOLD

Current Price

$11.49

Market Cap

267.7M

Sector

Utilities

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$3.48

Market Cap

130.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCYO
SERA
Founded
1976
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Precision Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
267.7M
130.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PCYO
SERA
Price
$11.49
$3.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
46.6K
57.1K
Earning Date
01-07-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
12.50
N/A
EPS
0.54
N/A
Revenue
$26,087,000.00
$95,000.00
Revenue This Year
N/A
$19.22
Revenue Next Year
N/A
$400.00
P/E Ratio
$20.98
N/A
Revenue Growth
N/A
1.06
52 Week Low
$9.65
$1.37
52 Week High
$12.99
$9.13

Technical Indicators

Market Signals
Indicator
PCYO
SERA
Relative Strength Index (RSI) 47.93 57.92
Support Level $11.39 $3.20
Resistance Level $11.80 $3.70
Average True Range (ATR) 0.35 0.28
MACD -0.03 0.04
Stochastic Oscillator 16.75 76.93

Price Performance

Historical Comparison
PCYO
SERA

About PCYO Pure Cycle Corporation

Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: